Identifying neuromuscular abnormalities in ThoBTB3 deficient mice, using the phenotypic assessment protocol - SHIRPA by Ana Alexandra Pinto Abreu
  
 
 
 
Mestrado em Biodiversidade, Genética e Evolução 
 
“Identifying neuromuscular abnormalities in 
RhoBTB3 deficient mice, using the 
phenotypic assessment protocol – SHIRPA” 
 
 
 
 
 
 
 
Ana Alexandra Pinto Abreu 
2011/2012 
 
 
F C U P  | 2 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ana Alexandra Pinto Abreu 
Mestrado em Biodiversidade, Genética e Evolução 
Departamento de Biologia 
2011/2012 
 
Orientador  
João Bettencourt Relvas, Investigador Principal, Instituto de Biologia Molecular e 
Celular 
 
 
 
“Identifying neuromuscular 
abnormalities in RhoBTB3 
deficient mice, using the 
phenotypic assessment 
protocol – SHIRPA” 
 
F C U P  | 3 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
Agradecimentos 
Os meus agradecimentos vão para todas as pessoas que directamente ou indirectamente 
me ajudaram neste percurso, mas em especial para aquelas que desde sempre e para 
todo o sempre sabem aquilo que eu sou capaz de fazer, e nunca deixaram de me apoiar e 
incentivar. Agradeço ao meu orientador João Bettencourt Relvas não só por me ter 
aceitado no laboratório, mas também por me incentivar a terminar este ciclo de estudos e 
ter dado toda a orientação e apoio necessários. Agradeço também à Doutora Ana 
Magalhães que me forneceu o suporte teórico e prático no que diz respeito aos testes de 
comportamento e que ainda me ajudou na componente estatística. A Doutora Carolina 
Lemos, que também me deu uma grande ajuda na componente estatista tem os meus 
agradecimentos. Agradeço também ao biotério, que cuida todos os dias dos nossos 
animais, em especial à Dª Isabel Duarte, que mais uma vez não foi apenas uma 
funcionária deste departamento, mas também uma amiga e continuará a ser a minha “2ª 
mãe”. Os meus agradecimentos vão também para todos os membros do grupo GCB – 
Joana, Sofia Domingues, Sofia Santos, Nuno Dias, Catarina Fonseca e Ana Seixas – que 
todos os dias levam comigo e com a minha música “foleira”. Neste magnifico grupo 
destaco a Pipas que esteve sempre disponível para esclarecer as minhas dúvidas, levar 
com as minhas manias e por varias vezes puxar-me as orelhas (com razão!) e a Débora 
que é mais uma amiga que uma colega de trabalho e com que partilhei duvidas, 
problemas, alegrias e que todos os dias esteve lá para me apoiar e por vezes chamar-me 
à razão.  
A pessoa a quem mais agradeço, que tudo fez para tornar isto possível, e que merece 
todo o meu apoio e admiração é a minha mãe, pois se não fosse a insistência dela eu não 
teria conseguido chegar até aqui. Os meus agradecimentos vão também para a minha 
irmã Virgínia, o meu avô António, a Marta, a Vânia, a Ruca, o Luís e claro a minha 
Neiinha, melhor amiga e parceira de sueca: “eu e ela, ela e eu, nós as duas…coiso!” Por 
ultimo e de extrema importância, agradeço ao meu namorado Zé, que foi a pessoa que 
mais tempo passou comigo e que mais vezes me disse: “Tu consegues! E eu ajudo-te!”. 
 
Obrigada a todos! 
 
F C U P  | 4 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
Resumo  
As proteínas RhoBTBs são Rho GTPases atípicas que estão envolvidas na regulação 
tumoral. Esta subfamília é constituída por três isoformas: RhoBTB1, RhoBTB2 e 
RhoBTB3. Além disso, foi observado pelo nosso laboratório que murganhos com ausência 
da proteína RHOBTB3 possuem um défice de mielinização no nervo óptico, resultado que 
foi previamente obtido através de análises histológicas deste tecido. De forma a avaliar 
uma possível existência de mais alterações neurológicas realizamos o primeiro screen do 
SHIRPA, que utiliza protocolos padronizados para uma avaliação funcional e 
comportamental que quantificam a expressão fenotípica no murganho. Este protocolo 
pode ser utilizado para identificar mutantes com anomalias neuromusculares. Todos os 
testes foram realizados em murganhos wild-type, heterozigóticos e knockout em três 
idades diferentes: um, três e seis meses. Os murganhos RhoBTB3 demonstraram 
alterações ao nível do peso, na reacção à transferência, na actividade locomotora, na 
elevação da cauda, na capacidade de fuga ao toque, na aproximação visual, na força ao 
agarrar, no beliscão no membro anterior, na manobra no ferro, no tempo de queda, na 
taxa cardíaca e no padrão de pegadas, evidenciando alterações comportamentais e 
fisiológicas.  
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Abstract 
RhoBTBs proteins are atypical Rho GTPase involved in tumor regulation. This subfamily 
consists in three isoforms: RhoBTB1, RhoBTB2 and RhoBTB3. Furthermore we observed 
that RHOBTB3 knockout mouse has a myelination deficit in optic nerve which was 
previously assessed by histological analyses. To evaluate if there were more neurological 
alterations we performed SHIRPA protocol primary screen, which utilizes standardized 
protocols for behavioral and functional assessment that provide a sensitive measure for 
quantifying phenotype expression in the mouse and can be used to identify mutants with 
neuromuscular abnormalities. All tests were performed in wild-type, heterozygous and 
knockout mice at three different time points: one, three and six months on an inverted light: 
dark cycle. RhoBTB3 mice exhibit alterations in weight, transfer arousal, locomotor activity, 
tail elevation, touch escape, visual placing, grip strength, toe pinch, wire maneuver, time to 
fall, heart rate and in footprint pattern evidencing behavior and physiological alterations.  
 
 
Key-words 
Rho GTPases; Myelination; RhoBTB3; Behavior tests; SHIRPA; Mouse. 
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1. Introduction 
 
Rho GTPases form a distinct family within the Ras-like protein superfamily, which also 
includes the Ras, Rab, Arf and Ran family. Rho proteins differ from other small GTPases 
because their sequences contain a Rho insert domain in the GTPase domain (Vega & 
Ridley 2008).The most well studied members of the Rho-family of small guanosine 
triphosphatases (Rho GTPases) act as binary molecular switches to control a wide variety 
of signalling pathways involved in many cellular processes. These signalling cascades, 
initiated by the stimulation of cell surface receptors, regulate gene transcription, vesicle 
trafficking and cytoskeletal reorganisation, which control  growth, differentiation, adhesion 
and cell migration (Feltri et al. 2008; Ellenbroek & Collard 2007; Aznar et al. 2004; Benitah 
et al. 2004; Gómez del Pulgar et al. 2005). It has also been reported that Rho GTPases 
are involved in most steps of cancer initiation and progression, including the acquisition of 
unlimited proliferation potential, survival and evasion from apoptosis, tissue invasion and 
the establishment of metastases (Vega & Ridley 2008).  
Rho GTPases are abundantly and ubiquitously expressed across species, from yeast to 
mammals, indicating that these proteins evolved early during evolution (Feltri et al. 2008; 
Ellenbroek & Collard 2007).  
There are 22 different Rho GTPases in mammals 
and they are divided into eight subfamilies: the 
RhoA-related subfamily (RhoA, RhoB, RhoC), the 
Rac1-related subfamily (Rac1, Rac2, Rac3, RhoG), 
the Cdc42-related subfamily (Cdc42, TC10, TCL, 
Chp/Wrch-2, Wrch1), the Rnd subfamily (Rnd1, 
Rnd2, RhoE/Rnd3), the RhoBTB subfamily, the 
TTF/RhoH subfamily, the RhoD/Rif subfalimy and 
the Miro subfamlily (Miro-1 and Miro-2) (fig. 1). 
Some subfamilies are classified as atypical 
GTPases because they are not regulated as 
classical GTPases. Atypical Rho GTPases include 
the Rnd, Miro and RhoBTB subfamilies, RhoH, Wrch1 and Chp (1, 2), and contain several 
types of domains not found in classical Rho proteins (fig.2) (Aspenström et al. 2007). 
 Rho GTPases 1.1
Figure 1 – The family of small RhoGTPases. 
(Ellenbroek, S. and Collard, J., 2007) 
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The most well studied RhoGTPases are RhoA, cdc42 and Rac, which have been shown to 
have key roles in different cellular processes. These RhoGTPases switch between an 
active GTP-bound and an inactive GDP-bound state (fig.3).  
 
 
 
 
 
 
 
 
 
 
Figure 2 - Schematic representation of the atypical Rho GTPases. (Aspenström et al. 2007) 
Figure 3 - Regulation of the RHO-family GTPase cycle. RHO-family proteins are inactive when bound to GDP 
and active when bound to GTP. Guanine nucleotide dissociation inhibitors (GDIs) prevent nucleotide 
exchange and keep the GTPases in the cytosol. Guanine nucleotide exchange factors (GEFs) activate RHO-
family GTPases by inducing GDP–GTP exchange. In the active, GTP-bound form, RHO-family proteins 
interact with and regulate the activity of endogenous effectors. GTPase-activating proteins (GAPs) inactivate 
RHO-family proteins by facilitating GTP hydrolysis. RHO-family proteins are isoprenylated, which allows 
membrane binding. (Aktories, K. 2011) 
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The GTP-GDP binding cycle is tighly regulated. The inactive form is activated at the cell 
membrane by GDP–GTP exchange by members of a large array (~80 proteins) of guanine 
nucleotide exchange factors (GEFs). The active GTP-bound state is terminated by GTP 
hydrolysis facilitated by certain GTPase-activating proteins (GAPs), a group that includes 
at least 60 members. A third family of regulatory proteins (comprising only three members) 
is that of guanine nucleotide dissociation inhibitors (GDIs), which keep Rho GTPases in 
the cytosol by interacting with their isoprenylated tail, thereby, preventing their activation. 
In the GTP-bound state, Rho-family proteins modulate the activity of many cellular 
effectors, such as protein kinases, phospholipases and adaptor proteins, that in some 
cases are Rho family specific (Aktories 2011; Jaffe & Hall 2005; Wennerberg & Der 2004; 
Villalonga & Ridley 2006; Aznar et al. 2004; Nodari et al. 2007; Moon & Zheng 2003).  
 
 
The evolution of complex nervous systems in vertebrates has been accompanied by, and 
probably dependent on, the acquisition of the myelin sheath. The myelin sheath is formed 
by myelin producing cells that wrap around axons. These myelinating cells are the 
oligodendrocytes in central nervous system (CNS) and Schwann Cells in peripheral 
nervous system (PNS) (Simons & Trotter 2007; Nodari et al. 2007) (fig.4).  
 
 
 
 
 
 
 
 
 
 
 Rho GTPases and myelination 1.2
A B 
Figure 4 - Myelinating Cells: A) Schwann Cells are the glial cells responsible for the myelination of the Peripheral Nervous 
System and B) Oligodendrocytes have the same role but in the Central Nervous System (Adapted from Sherman and 
Brophy, 2005). 
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Myelination in the nervous system is essential not only for the rapid and efficient 
propagation of action potentials, but also to maintain axonal integrity (Simons & Trotter 
2007; Sherman & Brophy 2005; Nodari et al. 2007).  
The involvement of Rho GTPases in the myelination of the vertebrate nervous system has 
been previously shown in our and other labs (Feltri et al. 2008; Benninger et al. 2007; 
Nodari et al. 2007; Pereira et al. 2009).  
 
 
The atypical Rho GTPases have recently been the focus of attention. RhoBTB proteins 
constitute a subfamily of atypical Rho GTPases. They were identified during the study of 
Rho-related protein-encoding genes in Dictyostelium discoideum, and orthologs have been 
found in numerous eukaryote clades, but are absent in plants, fungi and some metazoa 
(Berthold et al. 2008; Ramos et al. 2002). According to Rivero, et al. (2001), RhoBTB 
proteins differ from the classical ones in several aspects: they are much larger, with a size 
ranging from 65 KDa to 83 KDa while the classical ones have roughly 20 KDa; they do not 
cycle between GTP-GDP binding, and therefore do not depend on GAPs, GEFs or GDI 
regulation. RhoBTBs are regulated at the expression/degradation level, post-translational 
alterations and by protein-protein interactions, which might involve the additional domains 
that are present in RhoBTBs, such as the BTB domains that are not found in the classical 
Rho GTPases (Rivero et al. 2001). 
 
 Structure of RhoBTB proteins 1.3.1
The most prominent characteristic of RhoBTB proteins is their domain architecture: a 
GTPase domain is followed by a proline-rich region, a tandem of two BTB (Broad-
Complex, Tramtrack, and Bric à brac) domains, and a conserved C-terminal region (fig. 5). 
 
 
 
 Atypical Rho GTPases: RhoBTB subfamily 1.3
Figure 5 - Architecture of RhoBTB proteins. This includes the 3 human (Hs) subfamily members as well as the Drosophila (Dm) 
and Dictyostelium (Dd) orthologs. Simplified phylogenetic tree above illustrates the relationship among the proteins. Asterisks 
denote the positions of mutations in RhoBTB2 found in tumors. (Berthold et al. 2008). 
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In humans, the RhoBTB subfamily consists of 3 isoforms: RhoBTB1, RhoBTB2 and 
RhoBTB3 (Berthold et al. 2008; Ramos et al. 2002). Although RhoBTB3 is frequently left 
outside because of its divergent GTPase domain (Wennerberg & Der 2004), there is 
compelling architectural, phylogenetic, and possibly functional evidence for grouping this 
protein within the RhoBTB subfamily (Berthold et al. 2008). 
 Function of RhoBTB  1.3.2
According to Ellenbrock and Collard (2007), very little is known about the function of the 
RhoBTB proteins. These proteins do not seem to function as cytoskeletal organizers and 
are expressed in vesicular structures. RhoBTB2 has been suggested to be involved in 
protein degradation by binding of its BTB domain to an ubiquitin ligase scaffold protein. 
The localization of RhoBTB proteins in vesicular structures suggests a role in endocytosis 
or related processes. The role of RhoBTB genes as tumor suppressors, initially attributed 
only to RhoBTB2, and more recently to RhoBTB1 and also to RhoBTB3, is receiving 
increasing support. Nevertheless, the mechanisms by which RhoBTB proteins exert this 
and other roles remain largely speculative (Berthold et al. 2008).  
 Expression of RhoBTB genes 1.3.3
All 3 RhoBTB genes are ubiquitously expressed, both in humans and mice, although with 
differences in their expression levels and tissue distribution. In humans, RhoBTB1 shows 
high levels of expression in skeletal muscle and placenta and moderate levels in the 
stomach, kidney, testis, adrenal gland, and uterus.  RhoBTB3 is highly expressed in the 
placenta, testis, pancreas, adrenal and salivary glands, and neural and cardiac tissues. 
RhoBTB2 is very weakly expressed, but relatively high levels were detected in neural and 
cardiac tissues. All 3 genes are expressed in fetal tissues. The expression pattern of the 
mouse counterparts has been analyzed and is roughly comparable to that of the human 
genes. Mouse RhoBTB1 is highly expressed in the heart, testis, and kidney, and 
moderately in the uterus, liver, lung, stomach, placenta, and skeletal muscle. As in human 
tissues, RhoBTB2 is very weakly expressed in mouse tissues, with relatively higher 
expression levels in the brain. Mouse RhoBTB3 is strongly expressed in the brain, heart, 
and uterus, and moderately in all other tissues. In addition, the expression of 1 or more 
RhoBTB genes has been reported in numerous human and mouse cell lines using a 
reverse transcription polymerase chain reaction (RT–PCR) (Berthold et al. 2008; Ramos et 
al. 2002). 
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 Hypomyelination in the optic nerve of RhoBTB3 mice  1.4
Preliminary analyses show that the loss of RhoBTB3 leads to severe hypomyelination in 
the mutant optic nerve at P24. Heterozygous optic nerves are also affected but the 
hypomyelination is not as severe as in KO mice (fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transgenic and knockout technology in mice revolutionized biomedical research. 
Applications include discovering the biological function of a new gene, testing hypotheses 
about a known gene, and generating translational mouse models to develop treatments for 
human genetic disorders (Crawley 2008; Crawley et al. 1997),  such as Alzheimer's 
disease, Down's syndrome, Huntington's disease, schizophrenia and other neurobiological 
disorders (Brown et al. 2000). A robust and well- replicated phenotype is the key to 
 Genetically modified mice and behaviour 1.5
Figure 6 – Representative EM pictures of cross sections of the optic nerve of 24 days old wild 
type, heterozygous and mutant mice. Myelinated fibers are almost absent in the mutant optic 
nerve. Red arrows show  myelin outfoldings; Blue arrows show  naked axons and asterisks 
show astrocytic processes (unpublished data). 
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success. The consequences of the mutations can be understood by biochemical, 
anatomical, physiological, pathological, and behavioral assays. Behavior is the final output 
of the nervous system and analysis of behavioral outcomes in many genetically altered 
mice is essential to better understand the function of genes expressed in the brain 
(Crawley 2008) and the way in which mutations change gene function.  In many cases, the 
most noticeable difference between the transgenic mouse and its background strain is a 
change in behavior (Brown et al. 2000). The use of genetically engineered mice became 
widespread in behavioral neuroscience enabling researchers to define more precisely the 
role of specific proteins on neural function (Beeler et al. 2006; Lalonde et al. 2005; Rogers 
et al. 1999). However, the phenotype of a mutant mouse is not only the result of the 
individually targeted gene, but it also reflects the complex interactions with background 
genes, and unknown mutations in the genetic background (Crawley et al. 1997). Although 
early studies of transgenic, mutant, and knockout mice included very few behavioral tests 
(Brown et al. 2000), nowadays behavioral neuroscience has a long and illustrious 
literature, containing well-validated and carefully controlled methods for rodent behavioral 
testing of sensory abilities, motor functions, learning and memory, feeding and drinking, 
social interactions, drug and alcohol self-administration, and traits relevant to anxiety, 
depression, and schizophrenia (Crawley 2008; Hatcher et al. 2001). 
 
Before performing behavioral and functional analyses of a mouse phenotype it is 
necessary to make sure that the differences between phenotypes are the result of genetic 
alterations and are not due to other variables, and control them. These variables can be 
intrinsically linked to the animals – Genetic background, health status, age and sex – or 
can be external or environmental factors like the source of animals, housing conditions, 
type of food, drink and medications, environmental enrichment, social experiences, stress 
and even the conditions during the behavioral tests (Brown et al. 2000). 
 Genetic background 1.6.1
The genetic background choice of a mouse model is an important parameter for behavioral 
studies because mice strains differ significantly in behavior and physiology, endocrine and 
neural functions. When the aim is to create knockout (KO) animals, the choice of 
background strain also has to be appropriate. When heterozygous mice are bred to obtain 
 Behavioral experiments 1.6
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null homozygous (-/-), wild-type (+/+) and heterozygous (+/-) animals, littermates are 
appropriate controls. (Van Meer & Raber 2005; Brown et al. 2000). 
 Health status 1.6.2
Mice submitted to behavioral tests should be in good health. Strains of mice developed in 
facilities that have a conventional health status may have diseases that can alter the 
health and consequently behavior of the mice. Moreover, abnormal mice, such as mice 
that remain still and do not react to stimuli, due to injury or sickness, should be excluded 
(Brown et al. 2000). 
 Age and sex  1.6.3
In behavior tests the age is an important factor. At what age should the animals be used:  
at infancy, adolescence, adulthood or in old age? Different ages in behavior tests can 
affect the results because neural development of the brain and sexual differentiation 
continues beyond puberty. With knockout mice, the longevity of the strain can be affected 
by the targeted gene, so the absence of some genes can be lethal at birth, reducing 
animal life span and/or reproductive viability. As animals may perform differently at 
different ages, to determine correct ages for behavior tests is necessary to take into 
consideration the aim of the work. Sex differences should be considered as males and 
females because they can be differentially affected by gene mutations and therefore alter 
behavioral performance (Van Meer & Raber 2005; Brown et al. 2000). 
 Source of animals 1.6.4
Animals from different facilities may have been reared under different conditions and 
procedures, which can result in behavior alterations (Brown et al. 2000). 
 Environmental factors  1.6.5
Environmental factors must be taken into account because they can alter behavioral 
performance, and they can be several, like housing conditions (temperature and humidity 
changes, noise, cage type, luminosity cycle and diet), environmental enrichment, that 
facilitates neural and cognitive development and reduces anxiety, and alterations during 
the tests, like distractions from visual, auditory, and olfactory stimuli that may interfere with 
animal behavior. Even under controlled conditions, there are effects of the laboratory 
environment on behavior like the time when mice are being tested: day or night. (Van Meer 
& Raber 2005; Brown et al. 2000).  For example, Hossain et al. (2004) published that dark 
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phase improves genetic discrimination for some high throughput mouse behavioral 
phenotyping, while Kriegsfeld et al. (1999) found that nitric oxide synthase knockout mice 
had deficits in motor coordination when tested in the dark phase of the L:D cycle but not 
when tested in the light phase. They state, "Even though rodents are nocturnal animals, 
most behavioral studies, including learning, are conducted during the light period. Our 
findings emphasize the importance of examining the diurnal variations, especially in gene 
knockout research". As transgenic and knockout mice are expensive and many times 
difficult to maintain it is necessary to decide how many tests should be given to each 
animal and how many subjects per group should be tested. Before testing each mouse 
several times, one must consider whether the test affects the animal health and if it exits 
the possibility of the animals learn the test purpose. The way animals are handled before 
and during testing is also important because test behavior may be influenced by 
habituation to handling (Brown et al. 2000). 
 
SHIRPA (SmithKline Beecham Pharmaceuticals; Harwell, MRC Mouse Genome Centre 
and Mammalian Genetics Unit; Imperial College School of Medicine at St Mary’s; Royal 
London Hospital, St Bartholomew’s and the Royal London School of Medicine; Phenotype 
Assessment) uses standardized protocols for behavioral and functional assessment that 
provide a sensitive measure for quantifying phenotype expression in the mouse and can 
be used to identify mutants with neuromuscular abnormalities (Rafael et al. 2000; Rogers 
et al. 1999; de Visser et al. 2006; Masuya et al. 2005; J. P. Hatcher et al. 2001). 
SHIRPA is a three-stage protocol (Table 1) designed as a series of individual tests that in 
themselves provide quantitative and semi-quantitative data about an individual 
performance. Such test-specific performance is directly comparable between animals, over 
time, and between groups. In addition, the tests also provide the opportunity to define 
abnormalities or variation in the mouse, with each test providing information about the 
pattern of function of a particular system, for example the brain and neuromuscular 
system. Examination and analyses of data from all the tests can be summed to give a 
specific profile of function (Rogers et al. 1997). Therefore, new tests are constantly being 
developed and added to the existing  battery to provide a more complete behavioral profile 
of the animal being tested (Masuya et al. 2005). SHIRPA is commonly used in the 
characterization of the behavioral phenotype of inbred strains (Rogers et al. 1999), of 
  SHIRPA 1.7
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transgenic models of Alzheimer`s disease (Lalonde et al. 2005; Manso et al. 2012), of 
SOD1 gene mutant mice in Down’s syndrome (Lalonde et al. 2004) and of models of 
muscle pathologies  like dystrophies (Rafael et al. 2000). 
Table 1 - SHIRPA protocol 
SHIRPA PROTOCOL 
Primary Screen Secondary Screen Tertiary Screen 
Behavioral Observation 
Profile 
Locomotors Activity Anxiety 
 Food and water Intake Learning and Memory 
 Balance and Coordination Prepulse Inhibition 
 Analgesia Electroencephalography 
 Histology Nerve Conduction 
 Biochemistry Magnetic Resonance 
  Imaging 
Rogers et al. 1997 
 
1.7.1 SHIRPA primary screen 
The SHIRPA primary screen is designed to provide a behavioral and functional profile of a 
mouse being tested in less than 10 minutes and does not require any sophisticated 
measuring equipment (Rafael et al. 2000; Masuya et al. 2005). It comprises 40 measures 
and consists of quantitative and semi-quantitative observations of reflexes and basic 
sensorimotor functions as well as body weight and size (Lalonde et al. 2005; Masuya et al. 
2005). This test indicates defects in gait or posture, motor control and coordination, 
changes in excitability and aggression, lacrimation, piloerection, defecation and muscle 
tone. (Rogers et al. 1997, 2001). 
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1.7.2 SHIRPA secondary screen 
The secondary screen involves a comprehensive behavioral and functional screening 
battery of tests and pathological analysis. This includes measurement of spontaneous 
locomotors activity in the horizontal and vertical planes, and during these tests, food and 
water intake is also monitored. Tests of motor performance are carried out to confirm and 
quantify effects observed in the behavioral profile. Balance and coordination is quantified 
with an accelerating rotarod, which measures the ability of the mice to remain on a rotating 
drum. The effects on the perception of pain are measured with the mouse hot plate test, a 
well-established test of nociception. In addition, histopathological analysis of animals is 
carried out, and biochemical studies to measure serum urea, electrolyte, and blood 
glucose levels are performed to identify major metabolic deficits. These tests are carried 
out in conjunction with mass spectroscopic analysis of dried blood spot samples to screen 
for amino acid and intermediate metabolism defects (Rogers et al. 1997; Rogers et al. 
2001; Masuya et al. 2005). 
These primary and secondary protocols provide a basic phenotype assessment that can 
be used in a wide range of applications, including the characterization of spontaneous and 
induced mutants, and the analysis of transgenic and knockout phenotypes (Rogers et al. 
1997). 
 
1.7.3 SHIRPA tertiary screen 
The tertiary screening stage is tailored to the assessment of existing or potential models of 
neurological disease, as well as the assessment of phenotypic variability that may be the 
result of unknown genetic influences. This comprehensive assessment is complemented 
by more sophisticated tests like electromyography, electroencephalography, nerve 
conduction, and magnetic resonance imaging techniques, which employ well-established 
methods in the analysis of structural and functional abnormalities of the nervous system 
(Rogers et al. 1997; Rogers et al. 2001; Masuya et al. 2005). 
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Molecular techniques allowing in vivo modulation of gene expression have provided 
unique opportunities and challenges for behavioral studies aimed to understand the 
function of particular genes or biological systems under physiological or pathological 
conditions. Although various animal models are available, the laboratory mouse (Mus 
musculus) has unique features and is therefore a preferred animal model. The mouse 
shares many features at the anatomical, cellular, biochemical, and molecular level with 
humans. Also, the mouse shares with humans similar brain functions, such as anxiety, 
hunger, circadian rhythm, aggression, memory, sexual behavior and other emotional 
responses. Mice are also easily accommodated and easy to handle. They breed in 
captivity and the generation time is relatively short; they have an average lifespan of 2 
years (Van Meer & Raber 2005). 
 
 
RhoBTB3 is expressed in both neural and muscular tissue and its functions are not well 
characterized, also results from our lab suggest an essential role in optic nerve myelination 
for this protein. Thus, the aim of this study was to carry out a preliminary screen for 
neuromuscular defects in the RhoBTB3 knockout mouse using SHIRPA. 
 
 
 
 
 
 
 
 Why mice? 1.8
 Aim 1.9
F C U P  | 26 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
2. Materials and Methods 
2.1 Generation of experimental mice and genotyping 
2.1.1 Generation of RHOBTB3 straight knockout mice 
In collaboration with Francisco Rivero`s Group at the University of Hull, UK, we obtained 
the RHOBTB3 straight knockout mice. These transgenic mice were generated by the 
Sanger Institute, using standard techniques (fig.7).  
 
 
Figure 7 - Generation of RHOBTB3 straight knockout mice (Rivero et al.; unplublished) 
 
The mice have been available at the IBMC Animal Facility since January of 2011. Since 
then, we have carried out crosses between heterozygous animals to obtain: null 
homozygous (KO), heterozygous (HET) and wild type mice (WT). At the IBMC Animal 
Facility the animals are kept in a room with controlled temperature (22 degrees (ºC) +/- 
2ºC), humidity (55% +/- 10%), ventilation in a L: D cycle starting at 8:00am to 8:00pm. 
They are maintained in males and females groups in filter-top cages, have a maintenance 
diet (ad libitum) and distilled water. The mice have a conventional status and are always 
identified by ear punching and/or by paw tattoo, which are associated with a unique 
number. Each ear piece serves as a sample for genotyping. 
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2.1.2 Genotyping of RhoBTB3 mice by polymerase chain reaction (PCR) 
Mice genotype was identified by PCR analyses of DNA harvested from ear biopsies at 
P14. The genotyping procedure was done at the Cell Culture and Genotyping (CCGen) 
service in IBMC. In order to obtain the DNA, the digestion of the tissue sample was 
performed as follows: 300µl KL Buffer (10mMtris (pH7.5); 400mM sodium chloride (NaCl); 
2mM EDTA(pH8)= pHsol 7.3-7.5)), 10µl Proteinase K and 15µl 20%SDS were added to 
each sample, and incubated in a heating block with agitation at 55ºC, for 90 minutes (min). 
After digestion, samples were shortly centrifuged and 100µl of NaCl saturated solution 
were added, followed by a 15 min centrifugation, at maximum speed.  Supernatants were 
collected, and 800µl of 100% ethanol (EtOH) added. After DNA precipitation helped by 
gentle shaking, samples were centrifuged for 5 min, at maximum speed and supernatants 
discarded. Pellets were washed with 500µl of 70% EtOH, mixed, and centrifuged for 5 min, 
at maximum speed. The EtOH present in the microtube was carefully removed and the 
DNA pellets dryed for 10-15 min, before being resuspended in 50-100µl of water (H20). 
The microtubes were then placed in a heating block for 10 min at 65ºC to promote DNA 
hydration. For the PCR of genomic DNA, the PCR mix was prepared as indicated in Table 
2. The primers sequences are described below (Table 3). 
 
Table 2 – PCR MIX 
PCR MIX 
H2O (commercial) 3.75 µl 
Master mix Multiplex 5.0 µl 
Primer Rhobtb3_F 10mM 0.25 µl 
Primer Rhobtb3_R 10mM 0.25 µl 
Primer Cas_Rev 10mM 0.25 µl 
The amount of 0.5µl of DNA was added to 9.5µl of the PCR Mix to a total of 10µl for each 
reaction. Samples were inserted in a thermocycler for 150 min with the following 
amplification-scheme: 
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Step 1:          95ºC 5 min 
Step 2:          95ºC 30 sec 
                     55ºC 1 min 30 sec       30 cycles 
                     72ºC 30 sec 
Step 3:          60ºC 30 min 
Step 4:          ∞ 
 
Table 3 - Primers sequences 
Primers sequences 
Transgene Cas-Rev 
Forward Sequence 
(5`-3`) 
Reverse Sequence 
(5`-3`) 
Annealing 
temperature 
RhoBTB3 
TCGTGGTATCGTTA
TGCGCC 
TTTGAATCCCAGGTCTC
TGATG 
CGTGTAAATGTTCCATG
TATGTTGG 
55ºC 
A – Adenine; C – Cytosine; G – Guanine; T - Thymine 
Finally PCR reactions were loaded on a 1.5% agarose gel and the generated fragments 
weights were compared with a 100 bp ladder – 100 bp DNA Ladder from Solis BioDyne. 
The agarose gel products have 311bp which refers to KO and 642 bp which refers to WT, 
and finally observed under Ultraviolet light (fig.8). 
 
 
 
 
 
 
 
 
Figure 8 – Agarose gel for RHOBTB3 (CCGen) 
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2.2 Behavior tests 
Behavior tests were performed at 3 different developmental stages: 1, 3 and 6 month of 
age. The first stage matches the adult stage of the animal, the second the completion of 
myelination in the PNS and the last the completion of myelination in the CNS. Before 
testing, animals were kept in an external room for 10 to 15 days in order to adapt to the 
inverted L:D cycle (fig.9). The external room also has a controlled temperature (22ºC +/- 
2ºC), humidity (55% +/- 10%), ventilation and illumination, but an inverted L:D cycle 
starting at 8:00pm to 8:00am. Animals were maintained in males and females groups, with 
a maintenance diet and distilled water ad libitum. 
 
 
 
 
 
 
 
 
2.2.1 Adapted SHIRPA primary screen 
After the mentioned adaptation period, the mice were evaluated with an adapted protocol 
of SHIRPA (SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment) 
(Lalonde, R. et al., 2005) primary screen. This protocol is based on the SHIRPA primary 
screen protocol (http://www.mgu.har.mrc.ac.uk/mutabase/shirpa_1.html, accessed 
03.03.2011) and is divided in 6 parts – Table 4.  
Table 4 - SHIRPA primary screen protocol (adapted) 
Part Place / Action Observations Test time 
I Weighing container Weight 
5-10 seconds 
(sec) 
P0 days (d) 
Animal House 
Genotyping 
Standard L:D cycle 
 
L: 8am to 8pm / D: 8pm to 8am 
P21 d 
P75d 
P165 
Adaptation room 
15 days 
Inverted L:D cycle 
 
L: 8pm to 8am / D: 8am to 8pm 
BEHAVIOR 
TESTS 
• P30 to P40  
• P90  
• P180 
Figure 9 - Scheme used to invert the RhoBTB3 mice light cycle. 
F C U P  | 30 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
II Viewing jar 
Body position, spontaneous activity, 
respiratory rate and tremors.  
Manifestations of bizarre 
behavior/stereotyped. Seizures, 
compulsive licking, self-induced biting 
spatial disorientation. 
5 min 
 
 
Transfer Transfer reaction 
as fast as 
possible 
III Arena 
Locomotors activity, Palpebral 
Closure, Piloerection, Gait, Pelvic and 
Tail elevation and Touch escape 
5 min 
IV Tail suspension 
Resulting from manipulations 
involving the tail suspension (limb 
grasping, visual placing, grip strength, 
reflexes, coordination and balance, 
and others). 
5 min 
V Decubitus domain 
Autonomous behaviors resulting from 
the animal domain on ventral and 
dorsal decubitus. 
1 min 
VI Tunnel Footprint pattern: Gait registration 10-20 sec 
Final Observations Related general behaviors a few sec 
 
2.2.2 Material to perform SHIRPA protocol (fig.10): 
• Balance and container (a); 
• Viewing jar – Transparent acrylic jar, with a cylinder with 10 centimeters (cm) 
diameter, and 15 cm in height. The jar floor is in transparent acrylic, with 13x13 cm 
and holds with 0.5cm diameter (b); 
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• Arena (Clear Perspex arena) – Transparent acrylic box with 56cmx34cmx18.5cm 
(length (l) x width (w) x height (h)). The bottom has 11x11 cm square grids, and a 
metal wire with 65 cm length and 3 millimeters (mm) thickness crosses the arena 
diagonally at the top (c); 
• Metal grid - Grid with 36cm (l) x20cm (w) about 10mm in mesh size (d); 
• Probe wire (28 cm length), metallic tweezer and perch (a plastic perch covered 
with adhesive tape, with 30 cm length) (e); 
• Tunnel – A dark tunnel with 44 cm length and 11 cm diameter (f); 
• Drawing paper, brushes and black and red ink – To register footprint pattern   
 (non-toxic) (g); 
• Timer and registration material. 
 
 
 
 
 
 
 
 
 
 
 
a 
b 
c 
g 
f 
d 
e 
Figure 10 - Material to perform SHIRPA primary screen protocol. 
a 
b 
c 
d 
f g 
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2.2.3 Protocol 
Part I [balance] 
The animal was transferred from the maintenance cage into a scale container. Weight was 
recorded (grams (g)); 
Part II [viewing jar] 
The animal was then transferred into the viewing jar and timer was started. Several 
behaviors were observed and evaluated for 5 min without any interference. 
a) Body position 
0= Completely flat 
1= Lying on side 
2= Lying prone 
3= Sitting or standing 
4= Rearing on hind legs 
5= Repeated vertical leaping 
b) Spontaneous activity 
0= None, resting 
1= Casual scratch, groom, slow movement 
2= Vigorous scratch, groom, moderate movement 
3= Vigorous, rapid/dart movement 
4= Extremely vigorous, rapid/dart movement 
 
c) Respiratory rate 
0= Grasping, irregular 
1= Slow, shallow 
2= Normal 
3= Hyperventilation 
d) Tremors 
0= None 
1= Mild 
2= Marked 
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Part III [Arena] 
Rapidly, the animal was transferred from the viewing jar into the arena floor. Time was 
again recorded for 5 min. The following behaviors were observed and evaluated: 
a) Transfer reaction (animal reaction when it is placed in the arena floor) 
0= Coma 
1= Prolonged freeze, then slight movement 
2= Extended freeze, then moderate movement 
3= Brief freeze (few seconds), then active movement 
4= Momentary freeze, then swift movement 
5= No freeze, immediate movement 
6= Extremely excited (“crazy”) 
 
b) Locomotor activity – Number of squares entered by all 4 feet in the first 30 sec.  
 
c) Palpebral Closure (Observe both eyes and their closure): 
0= Eyes wide open  
1= Eyes semi-closed 
2= Eyes closed 
 
d) Piloerection (Observe body air and piloerection) 
0= Absent 
1= Present 
 
e) Gait 
0= Normal 
1= Fluid but abnormal 
2= Limited movement only 
3= Incapacity 
 
f) Pelvic elevation (Visually measure of the pelvis height of mouse in gait. Keep the eye 
level of the observer at the height of the mouse. Observations were performed from 
the side of the arena). 
0= Markedly flattened 
1= Barely touches 
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2= Normal (3mm elevation) 
3= Elevated (more the 3mm elevation) 
 
g) Tail elevation 
0= Dragging 
1= Horizontally extended 
2= Elevated / Straub tail (more than 45 degrees (º)) 
 
h) Touch escape (touching the animal with a finger, from the top. Observe how close 
the finger is when the mouse escapes) 
0= No response 
1= Mild (escape response to firm stroke) 
2= Moderate (rapid response to light stroke) 
3= Vigorous (escape response to approach) 
 
Part IV [Tail suspension] 
The animal was removed from the arena by holding the tail, in order to put it on the metal 
grid. During the journey, the following was observed:  
a) Trunk curl (The following was observed: if the mouse brings the upper body up by 
stooping the ventral side and shows a sit-up movement (trunk curl) when held up by 
tail. Twisting the upper body sideways is not trunk curl). 
0= Absent 
1= Present 
 
b) Limb grasping (The following was observed: if the mouse holds the forelimbs and 
hind legs together (Limb grasping) when held up by the tail). 
0= Absent 
1= Present 
 
c) Limb clasping (The following was observed: if the mouse crosses or closes the 
forelimbs and / or hindlimbs) 
0= Absent 
1= Present in forelimbs 
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2= Present in hindlimbs 
3= Present in both pairs of limbs 
 
d) Visual Placing (The mouse was hold up by the tail down to metal grid in the arena. 
See how close the mouse is to the metal grid when it extends the forelimbs to grasp 
the metal grid. Keep the eye level of the observer at the same height as the metal 
grid) 
0= None 
1= Upon nose contact 
2= Upon vibrissa contact 
3= Before vibrissa contact (18mm) 
4= Early vigorous extension (25mm) 
 
e) Grip strength (The mouse has hold by the tail and dragged in to the metal grid 
surface area. The grip strength was evaluated) 
0= None 
1= Slight grip, semi-effective 
2= Moderate grip, effective 
3= Active grip, effective 
4= Unusually effective 
 
f) Auricular reflex (While the animal was gripped on the grid, the proximal part of the 
lower eye canthus was touched with the wire prob. Retraction was evaluated) 
0= None  
1= Active retraction, as they quickly whipped 
2= Hyperactive retraction, like repetitive whipping 
 
g) Corneal Reflex (The mouse cornea was stimulated with the wire probe and mouse 
eyelids movement was observed) 
0= None 
1= Active single eye blink 
2= Multiple eye blink 
 
h) Toe pinch (Mouse medium finger of hind paw was squeezed using a metallic 
tweezers. During this procedure the hind limbs were kept away from grid) 
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0= None 
1= Discrete withdrawal  
2= Moderate withdrawal, not vigorous 
3= Energetic, quick withdrawal 
4= Very energetic and repeated flexions and extensions  
 
i) Wire maneuver (Mouse was hold by the tail and allowed to hold onto the wire of the 
arena with the forelimbs. Mouse body was kept parallel to the arena floor and 
released to see if the mouse could grasp the wire. Time: 30 sec. 
0= Active grip with hindlegs  
1= Difficulty to grip with hindlegs  
2= Unable to grip with hindlegs 
3=Unable to lift hindlegs, falls within seconds. 
4=Falls immediately 
 
j) Time to the animal fall (The time the animal remained in the wire (30 sec at 
maximum), if mouse got stuck in the wire, it would be ignored). 
 
k) Vertical perch (The animal was transferred into the center of the perch that was 
horizontal. The perch was then raised to the vertical) 
0= Falls 
1= Keeps 
2= Keeps up and walk slightly up / down 
3= Keeps moderately and walks up / down 
4= Keeps up and walks quickly up / down 
 
Part V [Mouse in decubitus restraint] 
a) Skin color (The color of the ventral sides of limbs were observed) 
0= Blanched 
1= Pink 
2= Bright, deep red flush 
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b) Heart rate (The observer forefinger was placed on the mouse chest to feel the heart 
rate). 
0= Slow, bradycardia 
1= Normal 
2= Fast, tachycardia 
 
c) Abdominal tone (The mouse abdomen was gently pressed with the forefinger to 
evaluate how hard the abdomen was). 
0= Flaccid, no return of cavity to normal 
1= Slight resistance 
2= Extreme resistance, board like 
 
d) Limb tone (The rear side of mouse hindlegs was pressed with the forefinger observer 
to evaluate how the mouse kicks back). 
0= No resistance 
1= Slight resistance 
2= Moderate resistance 
3= Marked resistance 
4= Extreme resistance 
 
e) Lacrimation (The mouse was hold in restraint and observed if the lacrimation fluids 
flow out). 
0= Absent 
1= Present 
 
f) Negative geotaxis (The animal was transferred into the metal grid, by holding the tail. 
When released, the mouse would move forward. The metal grid was turned 90º so 
that the mouse was turned head down. The time was turn for 30 sec and mouse 
movements were observed). 
0= Turns and climbs the grid 
1= Turns but then freezes 
2= Moves, but fails to turn 
3= Does not move within 30 sec 
4= Falls off 
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Part VI [Tunnel] 
a) Footprint pattern (The mouse paws were 
painted with non-toxic ink, in different 
colors for the front and hind limbs. The 
mouse was then placed at the beginning 
of the tunnel, with a sheet of paper 
under.) Then, 5 measurements are 
obtained: Step length, width hindlimb 
steps, width forelimb steps, overlap, 3 
fingers distance and 5 fingers distance 
(fig. 11). 
 
 
 
 
 
Final observations 
a) Aggression (It was observed if the mouse defied or/and bit) 
0= None 
1= Provoked biting or attack 
b) Irritability (It was observed if the mouse resisted violently when held is restraint)) 
0= None  
1= Struggle during spine restraint. 
c) Fear (It was observed if the mouse froze whenever it was transferred from a place to 
another) 
0= None 
1= Freezes during transfer arousal 
 
 
 
Figure 11 - Measurements of footprint pattern 
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d) Vocalization (It was observed if mouse squeaked during the tests) 
0= None 
1= Provoked during handling 
 
e) Urination: The number of micturition was recorded 
 
f) Defecation: The number of stools were recorded 
 
g) Any incidents, bizarre or stereotyped behavior were recorded separately over the 
test. 
 
 
2.3 Statistical analysis 
All results were analyzed with IBM SPSS Statistics 19.  
First, an analysis was made between males and females of the same genotype and time 
point in order to check if there were differences between them. Then, separating males 
and females, we analyzed differences between different genotypes within the same time 
point in order to verify if the genotype causes behavioral differences. Finally, again 
separating males and females alterations were analyzed between different time points 
within the same genotype, in order to check if there is a phenotypic variation in a particular 
genotype according to the time. The data was divided into four groups and separately 
analyzed with the respective statistical test – Table 5. 
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Table 5 - Data analyses and respective statistical test 
Category Behavior test Statistical test 
Numeric 
Weight Independent T-samples T test 
(Levene`s Test for Equality of 
variances and t-test for Equality of 
Means) 
+ 
Group Statistics (n (number of 
animals), Mean, Standard Deviation 
(SD)) 
Locomotor Activity 
Time to the fall 
Micturition 
Defecation 
>2categorizations 
Body position 
Mann-Whitney Test 
+ 
Group Statistics (n, Median) 
 
Spontaneous activity 
Respiratory Rate 
Tremors 
Transfer Arousal 
Palpebral Closures 
Gait 
Pelvic Elevation 
Tail elevation 
Touch escape 
Limb clasping 
Visual Placing 
Grip Strength 
Pinna Reflex 
Corneal Reflex 
Toe Pinch 
Wire maneuver 
Vertical perch 
Skin color 
Heart rate 
Abdominal Tone 
Limb tone 
Negative geotaxis 
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2 categorizations 
Piloerection 
Crosstabs 
+ 
Chi-Square Tests 
+ 
Group Statistics (n, Median) 
 
Trunk curl 
Limb grasping 
Lacrimation 
Aggression 
Irritability 
Fear 
Vocalization 
Footprint pattern 
Stride length 
Mann-Whitney Test 
+ 
Group Statistics (n, Mean, SD) 
 
Hindlimbs step width 
Forelimbs step width 
3 fingers 
5 fingers 
Overlap 
Data are shown as the mean +/- standard deviation of the mean for numeric data and by 
median and interquartile range for categorizations data. Significance was set as n.s. (not 
statistical significance) for p>0.05 and the significance for the different categories: 
Differences between males and females: * P< 0,05; ** P<0,01; *** P<0,001; Differences 
between WT and HET: (a) P< 0,05; (aa) P< 0,01; (aaa) P< 0,001; Differences between WT and 
KO: (b) P< 0,05; (bb) P< 0,01; (bbb) P< 0,001; Differences between HET and KO: (c) P< 0,05; 
(cc) P< 0,01; (ccc) P< 0,001; Differences between 1month and 3 months: (d) P< 0,05; (dd) P< 
0,01; (ddd) P< 0,001; Differences between 1 month and 6 months: (e) P< 0,05; (ee) P< 0,01; 
(eee) P< 0,001; Differences between 3 months and 6 months: (f) P< 0,05; (ff) P< 0,01; (fff) P< 
0,001. 
 
2.4 Number of animals (n) 
A total of 157 animals were used in behavior tests: 82 males and 75 females divided per 3 
genotypes – KO (null homozygous), HET (heterozygous) and WT (Wild type) – and age – 
P40 (40 days), P90 (90 days) and P180 (180 days) – according to the Table 6. 
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Table 6 - Used animals divided per genotypes and age 
 
KO HET WT 
 
1 
Month 
3 
Months 
6 
Months 
1 
Month 
3 
Months 
6 
Months 
1 
Month 
3 
Months 
6 
Months 
Total 
Males 7 7 8 10 10 10 10 10 10 82 
Females 5 7 5 10 9 10 10 9 10 75 
Total 12 14 13 20 19 20 20 19 20 157 
Whenever possible, the same animal was not used more than twice in order to avoid the 
tests learning. 
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3. Results 
3.1 RhoBTB3 colony does not follow the expected Mendelian 
distribution of offspring. 
The first Mendel Law or Law of Independent Segregation states that in crosses of 
heterozygous individuals the genotype of the offspring is 50% heterozygous (HET), 25% 
homozygous (KO) and 25% wild-type (WT) (Monaghan & Corcos 1984). In the 696 mice 
born from heterozygous crosses, 429 were HET (+/- 62%), 60 KO (+/- 8%) and 207 WT 
(+/- 30%) (fig. 12).  
This proportion represents a significant skewing from the expected Mendelian distribution. 
 
3.2 SHIRPA results 
SHIRPA comprises a set of standardized experimental procedures designed to 
characterize the phenotype of transgenic mice. It was designed to test primarily 
neuromuscular, motor and sensory function. However, modified SHIRPA screens of 
increasing complexity have also been used to characterize neuropsychiatric function.  
Because SHIRPA has been successful in detecting and characterize several   
neuromuscular phenotypes in transgenic mice, we used it here to screen for phenotypes in 
Figure 12 - Percentages of observed offspring genotypes in the RhoBTB3 mice colony. 
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the RhoBTB3 mice colony. Mice to be analyzed were grouped according to age, in groups 
of 1, 3 and 6 months. Unless stated, for statistical analysis we used t-test for Equality of 
Means and the non-parametric significance Mann-Whitney test (see material and methods 
section). 
 
3.2.1 Weight variation   
The t-test for Equality of Means revealed significant differences in weight between 
genotypes (table 7). At 1 month, KO males were lighter than WT and HET and HET 
females heavier than KO and WT. In the 3 month group, KO males were lighter than WT 
and HET and KO females were also lighter than WT and HET. At 6 months, only the 
females show statistically significant differences with KOs being lighter than WT and HET 
mice. As expected, in the three genotypes males were always heavier than females. In 
males and females of the three genotypes there was a statistically significant increase in 
the weight of the mice with age (table 7). 
Table 7 - Weight results for different genotypes in each time point and between males and 
females. 
Weight 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 17,9 ± 5,6 15,8 ± 2,4 20,8 ± 2,1 18 ± 2,3 
(*)(a)(cc)
 13,57 ± 2,3 
(b)(ccc)
 14 ± 1,4 
3 months 28,7 ± 2,8 23,11 ± 2,4 
(***)
 28,3 ± 3,2 24 ± 3,1 
(**)
 24 ± 3,1 
(bb)(c)
 18,57 ± 1,3
 (**)(bbb)(cc)
 
6 months 32,8 ± 2,86 26,5 ± 2,51
(***)
 32,5 ± 3,1 24,7 ± 1,83 
(***)
 31 ± 9,4 22,2 ± 2,1
 (bb)(c)
 
Each value is expressed as mean ± SD. The values are expressed in gramme. 
(*)
 P< 0,05, 
(**)
 P<0,01, 
(***)
 P<0.001 refers to 
differences between males and females. 
(a)
 P<0,05 refers to differences between WT and HET.
 (b)
 P<0,05, 
(bb)
 P<0,01,
 (bbb)
 
P<0,001 refers to differences between WT and KO. 
(c)
 P<0,05; 
(cc)
 P<0,01;
 (ccc)
 P<0,001 refers to differences between HET 
and KO. 1 month WT males n=10; 1 month WT females n=10; 1 month HET males n=10; 1 month HET females n=10; 1 
month KO males n=7; 1 month KO females n=5; 3 months WT males n=10;  3 months WT females n=9; 3 months HET 
males n=10; 3 months HET females n=9; 3 months KO males n=7; 3 months KO females n=7; 6 months WT males n=10;  6 
months WT females n=10; 6 months HET males n=10; 6 months HET females n=10; 6 months KO males n=8; 6 months KO 
females n=5. 
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It was also visually noted that RHOBTB3 mice with 14 days have different sizes: KO was 
smaller; WT larger and HET had an intermediate size (fig. 13). 
 
 
 
 
 
 
3.2.2 Variation of behaviors recorded in arena 
3.2.2.1 Transfer reaction 
The Mann-Whitney test revealed significant differences in HET females in relation to the 
transfer reaction level. The categorization was done as described in the material and 
methods section. At 6 months of age all the animals are in the “No freeze” category, 
whereas at 3 month of age some of them are in the “Momentary freeze category”. The 
number of mice that are in this category decreased over time, probably reflecting some 
degree of acquired familiarity with their surroundings. This might explain the statistic 
significant difference between mice with 1 and 6 months of age. Males did not differ 
significantly (table 8). 
Table 8 - Transfer Arousal results for different genotypes over the time points. 
Transfer Arousal 
 
WT HET KO 
 
1 month 3   months 6 months 1 month 3 months 6 months 
1 
month 
3 
months 
6 
months 
Males 5 (4,75-5) 5 (2,75-5) 
5 (3.75-
5) 
ns
 
5 (5-5) 5 (4,25-5) 5 (3-5) 
ns
 5 (5-5) 5 (4-5) 
5 (3,5-
5) 
ns
 
Females 5 (4-5) 5 (4.25-5) 5 (5-5) 
ns
 5 (4-5) 5 (4,5-5) 5 (5-5)
(e)
 5 (5-5) 5 (3-5) 5(5-5)
ns
 
Each value is expressed as median ± IQ in parenthesis. ns, not significant. The values are expressed in categories.
 (e)
 P< 
0,05 refers to differences between 1 month and 6 months. 1 month HET females n=10; 3 months HET females n=9; 6 
months HET females n=10. 
 
 
Figure 13 - RHOBTB3 KO, HET and WT mice (P14) size. 50 ml falcon was used as reference to compare the sizes. 
 
WT 
KO 
WT HET 
KO 
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3.2.2.2 Locomotor Activity 
There were significant differences in Locomotor Activity in HET males between the 1 and 
the 6 month groups. The HET females had a gradual increase of locomotor activity that 
was significant between 3 and 6 months of age and between 1 and 6 months of age WT 
and KO animals do not have significant differences (table 9). 
Table 9 - Locomotor Activity results for different genotypes over the time points. 
 
Locomotors Activity 
 
WT HET KO 
 
1 month 3 months 6 months 1 month 3 months 6 months 1 month 3 months 6 months 
Males 
14,6 ± 
5,44 
16,6 ± 
6,98 
17,8 ± 
4,8 
ns
 
18,2 ± 
4,37 
16,4 ± 
5,4 
14,5 ± 
2,27 
(e)
 
14,57 ± 
4,65 
15,14 
±7,65 
16,25 ± 
9,4
 ns
 
Females 
16,9 ± 
3,51 
17 ± 
3,58 
18,3 
±5,23 
ns
 
15,6 ± 
4,65 
16,56 ± 
3,9 
22,1 ± 
5,3 
(ee)(f)
 
15,2 ± 
2,78 
15,57 ± 
5,62 
18,4 ± 
6,54
 ns
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in squares number. 
(e)
 P< 0,05, 
(ee)
 P< 
0,01 refers to differences between 1 month and 6 months. 
(f)
 P< 0,05 refers to differences between 3 months and 6 months. 
1 month HET males n=10; 1 month HET females n=10; 3 months HET males n=10; 3 months HET females n=9; 6 months 
HET males n=10; 6 months HET females n=10. 
 
3.2.2.3 Tail Elevation 
There were significant differences in the Tail Elevation test in HET males between the 1st 
month, an age when the tail is more often in a horizontal position, and the 3rd month, when 
the tail is more frequently elevated.  In the 6th month group the tail was more frequently 
elevated. WT, KO mice and HET females do not showed significant differences (table 10). 
Table 10 – Tail elevation results for different genotypes over the time points. 
 Tail elevation 
 WT HET KO 
 1 month 3 months 6 months 1 month 3 months 6 months 1 month 3 months 6 months 
Males 1 (1-2) 2 (1-2) 1,5 (1-2) 
ns
 
1 (1-2) 2 (1,75-2) 
(d)
 2 (1,75-2) 
(e)
 2 (1-2) 2(2-2) 2 (2-2) 
ns
 
Females 2 (1,75-2) 2 (1,5-2) 2 (1-2) 
ns
 2 (1-2) 2 (1,5-2) 1(1-2) 
ns
 2 (1-2) 2 (1-2) 1(1-2) 
ns
 
Each value is expressed as median ± IQ in parenthesis. ns, not significant. The values are expressed in categories.
 (d)
 P< 
0,05 refers to differences between 1month and 3 months.
 (e)
 P< 0,05 refers to differences between 1 month and 6 months. 1 
month HET males n=10; 3 months HET males n=10; 6 months HET males n=10. 
3.2.2.4 Touch escape 
There were significant differences in the Touch Escape test between genotypes. At one 
month of age, the response of KO females was milder than that of WT females. At 3 
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months, KO females had more moderate responses compared with both WT and HET 
mice. Surprisingly, HET had more vigorous responses compared to WT. At 6 months, the 
response of KO females was milder than that of WT. Although there is no statistical 
significance, 1month KO males appear to have less vigorous responses than WT and HET 
males with 1 month (fig. 14). 
 
 
 
 
 
 
 
 
 
In KO, HET and WT males the touch escape response varies significantly along the 3 time 
points (fig. 15). In females, the variation is similar to the one described for males, with the 
exception that there was no significant difference in the response for KO females of 
different ages (fig. 15). 
 
 
 
Figure 14 - Significant differences between genotypes at 1, 3 and 6 months in Touch Escape test. 
(a)
 P<0,05 refers to 
differences between WT and HET.
 (b)
 P<0,05, 
(bb)
 P<0,01
 
refers to differences between WT and KO. 
(cc)
 P<0,01 refers to 
differences between HET and KO.  
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3.2.3 Variation of behaviors recorded in tail suspension 
3.2.3.1 Visual Placing 
There were significant differences in Visual Placing between genotypes. At 1 month, KO 
males extended the forelimbs before vibrissae contact significantly more times than HET 
males. KO females with 6 months extended the forelimbs before vibrissae contact 
significantly more times than WT females, and have less vigorous responses. At three 
months there are no significant differences (fig. 16).  
 
 
 
 
 
 
 
Figure 15 - Significant differences between 1, 3 and 6 months in each genotype in Touch Escape test. 
(d)
 P< 0,05 refers to 
differences between 1month and 3 months.
 (e)
 P< 0,05 refers to differences between 1 month and 6 months. 
(f)
 P< 0,05 refers to 
differences between 3 months and 6 months.  
 
Figure 16 - Significant differences between genotypes at 1, 3 and 6 months in Visual Placing Test. 
(b)
 P<0,05 refers to differences 
between WT and KO. 
(cc)
 P<0,01 refers to differences between HET and KO. 
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WT females extended the forelimbs before vibrissae contact significantly more times at 1 
month compared to 6 months. 3 month HET males appear, although not statistically 
significant, reduction of vigorous responses (fig. 17). 
 
 
 
 
 
 
 
 
3.2.3.2 Grip Strength 
There were significant differences in Grip Strength at the ages of 1 and 6 months between 
KO, and WT males groups where the grip strength values were higher; Six months HET 
males have slighter grip compared with WT males. In three month old KO females the 
number of animals with slight grip was higher than in WT females (fig. 18). 
 
 
 
 
 
 
 
Figure 17 - Significant differences between 1, 3 and 6 months in each genotype in Visual Place test. 
(e)
 P< 0,05 refers to 
differences between 1 month and 6 months. 
Figure 18 - Significant differences between genotypes at 1, 3 and 6 months in Grip Strength test. 
(a) 
P<0,05 refers to 
differences between WT and HET.
 (b)
 P<0,05 refers to differences between WT and KO. 
Grip Strength 
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In KO males there was a significant variation over the 3 time points in Grip Strength. At 1 
month the number of mice with slight grip was higher than at 3 months, when were more 
animals with moderate grip (fig. 19). 
 
 
 
 
 
 
 
 
 
 
3.2.3.3 Toe Pinch 
There were significant differences in the Toe Pinch test between genotypes (table 11). 
Three months KO females have significantly more energetic responses compared with 
HET females. Six months HET males have significantly more moderate responses 
compared with WT males that have more energetic responses. One month animals do not 
have significant differences. HET and WT males and females and KO males show 
significant differences over the 3 time points in the Toe Pinch test. KO females do not 
show any significant differences with time (table 11). 
 
 
 
 
 
Figure 19 - Significant differences between 1, 3 and 6 months in each genotype in Grip Strength test. 
(d)
 P< 0,05 refers to 
differences between 1month and 3 months. 
 
Grip Strength 
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Table 11 – Toe Pinch results for differences between genotypes in each time point and 
between males and females.  
Toe Pinch 
 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 0,5 (0-3) 0,5 (0-2,25)
 ns
 2 (0-3) 1 (0-3)
 ns
 1 (0-3)  2 (1,5-3) 
ns
 
3 months 2 (0-3) 0 (0-3) 0 (0-0,25)
(dd)
 0 (0-0,5) 1 (0-3) 
ns
 3 (0-3) 
(c)
 
6 months 3 (3-3) 
(e)(f)
 3 (1,75-3)
(e)
 2 (0,75-3) 
(a)(f)
 3 (2,5-3)
(ff)
 3 (3-3)
(e)
 3 (1-3) 
ns
 
Each value is expressed as median ± IQ in parenthesis. ns, not significant. The values are expressed in categories.
 (dd)
 
P<0,01 refers to differences between 1month and 3 months. 
(e)
 P< 0,05 refers to differences between 1 month and 6 months. 
(f)
 P< 0,05; 
(ff)
 P< 0,01 refers to differences between 3 months and 6 months. 1 month WT males n=10; 1 month WT females 
n=10; 1 month HET males n=10; 1 month HET females n=10; 3 months WT males n=10; 3 months WT females n=9; 3 
months HET males n=10; 3 months HET females n=9; 3 months KO females n=7; 6 months WT males n=10; 6 months WT 
females n=10; 6 months HET males n=10; 6 months HET females n=10; 6 months KO females n=8. 
 
3.2.3.4 Wire Maneuver 
In 6 months old males there were significant differences in the Wire Maneuver test 
between genotypes. KO males hold up better the wire than WT and HET males. At 1 and 3 
months there are not significant differences. There were also some significant differences 
with age in HET and KO males, and in WT and HET females. WT males and KO females 
do not showed significant differences over time (table 12). 
Table 12 – Wire Maneuver results for different genotypes in each time point and between 
males and females. 
Each value is expressed as median ± IQ in parenthesis. ns, not significant. The values are expressed in categories.
 (d)
 
P<0,05 refers to differences between 1month and 3 months. 
(e)
 P< 0,05; 
(ee)
 P< 0,01 refers to differences between 1 month 
and 6 months. 
(f)
 P< 0,05 refers to differences between 3 months and 6 months. 1 month WT females n=10; 1 month HET 
males n=10; 1 month HET females n=10; 1 month KO males n=7; 3 months WT females n=9; 3 months HET males n=10; 3 
months HET females n=9; 3 months KO males n=7; 6 months WT females n=10; 6 months HET males n=10; 6 months HET 
females n=10; 6 months KO males n=8. 
 
 
Wire Maneuver 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 1,5 (0-2,25) 0 (0-1) 1 (0-2) 0,5 (0-1) 2 (1-3) 
ns
 0 (0-1,5) 
ns
 
3 months 2 (0,75-3) 1 (0,5-2,5) 2,5 (1-3)
(d)
 1 (1-2)
(d)
 1 (1-4) 
ns
 1 (1-1) 
ns
 
6 months 1,5 (0,75-3) 2 (1-3)
(ee)
 1 (1-2,25) 1,5 (1-2,25) 0 (0-3) 
(b)(c)(e)(f) 
1 (0-3,5) 
ns
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3.2.3.5 Time to fall 
The Time to Fall test showed some significant differences between genotypes (table 13). 
The 6 months KO males take more time (an average of 27.5 seconds) to fall compared to 
HET (20.6 sec) and WT (16.1 sec) mice. At 1 and 3 months there are not significant 
differences between genotypes. KO males take significant more time to fall with increasing 
age. WT and HET mice and KO females did not show significant differences (table 13). 
 
Table 13 - Time to fall results for different genotypes in each time point and between 
males and females. 
Time to the fall 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 19,3 ± 10,25 
ns
 25,2 ± 9,09 
ns
 23,6 ± 10,99 
ns
 27,9 ± 4,12 
ns
 17,14 ± 10,51  24,8 ± 11,63 
ns
 
3 months 19,4 ±16,20 
ns
 24,33 ± 10 
ns
 16,2 ± 13,11 
ns
 
23,78 ± 10,96 
ns
 
16,29 ±13,5 
ns
 28 ± 3,42 
ns
 
6 months 16,1 ± 11,09 21,8 ± 10,92 
ns
 20,6 ± 11,01 23,2 ± 9,69 
ns
 27,5 ± 4,2 
(b)(e)
 18,6 ± 15,65 
ns
 
Each value is expressed as mean ± SD. Values are expressed in seconds. ns, not significant. . 
(b)
 P<0,05 refers to 
differences between WT and KO. 
(e)
 P< 0,05 refers to differences between 1 month and 6 months. 1 month KO males n=7; 6 
months WT males n=10; 6 months KO males n=8;  
  
3.2.4 Variation of behaviors recorded in restrained mice  
3.2.4.1 Heart rate 
There were significant differences in the Heart rate test between genotypes, with both 
male and female KO mice having, in general, a significant higher heart rate than HET and 
WT mice (table 14). Between WT and HET mice there are no significant differences. 
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Table 14 - Heart rate results for different genotypes in each time point and between males 
and females. 
Heart Rate 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 1,5 (1-2) 1 (1-2) 1 (1-1) 1 (1-1,25) 2 (2-2) 
(b)(ccc)
 2 (1,5-2) 
(c)
 
3 months 1 (1-2) 
ns
 1 (1-1,5) 1 (1-2) 
ns
 1 (1-1) 2 (1-2) 
ns
 2 (2-2) 
(bb)(cc)
 
6 months 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 2 (1,25-2) 
(b) (c)
 2 (1-2) 
(c)
 
Each value is expressed as median ± IQ in parenthesis. ns, not significant The values are expressed in categories..
 (b)
 
P<0,05, 
(bb)
 P<0,01
 
refers to differences between WT and KO. 
(c)
 P< 0,05; 
(cc)
 P<0,01; 
(ccc)
 P< 0,001 refers to differences 
between HET and KO. 1 month WT males n=10; 1 month WT females n=10; 1 month HET males n=10; 1 month HET 
females n=10; 1 month KO males n=7; 1 month KO females n=5; 3 months WT females n=9; 3 months HET females n=9; 3 
months KO females n=7; 6 months WT males n=10;  6 months WT females n=10; 6 months HET males n=10; 6 months HET 
females n=10; 6 months KO males n=8; 6 months KO females n=5. 
 
3.2.4.2 Negative Geotaxis test 
There were significant differences in the Negative Geotaxis test in KO males over time 
(table 15). Although statistically significant such differences are probably not biologically 
significant.  WT and HET mice and KO females did not show significant differences. 
Table 15 - Negative geotaxis results for different genotypes over the time points. 
Negative geotaxis 
 
WT HET KO 
 
1 month 3 months 6 months 1 month 3 months 6 months 1 month 3 months 6 months 
Males 0 (0-1) 
ns
 0 (0-0,25) 
ns
 0 (0-0) 
ns
 
0 (0-1) 
ns
 
0 (0-0) 
ns
 0 (0-0) 
ns
 0 (0-1) 0 (0-0) 0 (0-0)
(e)
 
Females 0 (0-0,25) 
ns
 0 (0-0) 
ns
 0 (0-0,25) 
ns
 
0 (0-1) 
ns
 
0 (0-0,5) 
ns
 0 (0-1) 
ns
 0 (0-1,5) 
ns
 0 (0-0) 
ns
 0 (0-0) 
ns
 
Each value is expressed as median ± IQ in parenthesis. The values are expressed in categories. ns, not significant. 
(e)
 P< 
0,05 refers to differences between 1 month and 6 months. 1 month KO males n=7; 3 months KO males n=7; 6 months KO 
males n=8. 
 
3.2.5 Variation of micturition  
There were significant differences in the micturition of HET males and females over the 
time points analyzed. Apparently, WT males have a higher micturition than WT females 
and the same happens in KO with the exception of 1 month animals (table 16). 
 
F C U P  | 54 
“Identifying neuromuscular abnormalities in RhoBTB3 deficient mice, using the phenotypic assessment protocol – SHIRPA” 
 
 
 
Table 16 - Micturition results for different genotype over time. 
Micturition 
 
WT HET KO 
 
1 month 3 months 6 months 1 month 3 months 6 months 1 month 
3 
months 
6 
months 
Males 
2,2 ± 
1,75 
2,8 ± 
3,49 
5,5 ± 
1,51 
ns
 
1,7 ± 1,6 2 ± 2,12 6,2 ± 1,69 
(e)(f)
 
2,43 ± 
1,13 
3 ± 1,41 
5,13 ± 
1,81 
ns
 
Females 
1,4 ± 
1,43 
1,22 ± 
1,39 
5,4 ± 
1,58 ns 
1,7 ± 
1,16 
1,33 ± 
1,23 
4,1 ± 1,45 
(e)(f)
 2,8 ± 1,3 
1,57 ± 
1,27 
4 ±2 
ns
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in micturition number.
 (e)
 P< 0,05 refers 
to differences between 1 month and 6 months.
 (f)
 P< 0,05 refers to differences between 3 months and 6 months. 1 month 
HET males n=10; 1 month HET females n=10; 3 months HET males n=10; 3 months HET females n=9; 6 months HET 
males n=10; 6 months HET females n=10. 
 
3.2.6 Variation of Footprint pattern 
3.2.6.1 Stride Length  
The footprint test showed some significant differences between genotypes in 1 month 
females and six month males (table 17). At 3 months there were no significant differences 
between genotypes. As expected, the stride length increased over time in both males and 
females of all genotypes, with the exception of WT females between the 3rd and 6th month 
of age (table 17). 
Table 17 - Stride length results for different genotypes at each time point and between 
males and females.  
Stride length 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 4,64 ± 0,15 
ns
 4,97 ± 0,18 4,89 ± 0,18 
ns
 4,59 ± 0,2 4,61 ± 0,3
 ns
 4,3 ± 0,23 
(b)
 
3 months 5,6 ± 0,35 
(d)
 6,49 ± 0,62 
(d)
 6,08 ± 0,25 
(dd)
 5,9 ± 0,25 
(dd)
 5,43 ± 0,29 
ns
 5,43 ± 0,32 
(d)
 
6 months 5,63 ± 0,28 
(ee)
 6,17 ± 0,24 
(ee)
 6,47 ± 0,16 
(a)(eee)
 6,47 ± 0,16
 (ee)
 5,77 ± 0,34
(e)
 6,06 ±0,28 
(ee)
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in cm.
 (a)
 P< 0,05 refers to differences 
between WT and HET. 
(b)
 P< 0,05 refers to differences between WT and KO. 
(d)
 P< 0,05, 
(dd)
 P< 0,01 refers to differences 
between 1month and 3 months. 
(e)
 P< 0,05, 
(ee)
 P< 0,01 refers to differences between 1 month and 6 months. 1 month WT 
males n=10; 1 month WT females n=10; 1 month HET males n=10; 1 month HET females n=10; 1 month KO males n=7; 1 
month KO females n=5; 3 months WT males n=10;  3 months WT females n=9; 3 months HET males n=10; 3 months HET 
females n=9; 3 months KO males n=7; 3 months KO females n=7; 6 months WT males n=10;  6 months WT females n=10; 6 
months HET males n=10; 6 months HET females n=10; 6 months KO males n=8; 6 months KO females n=5. 
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3.2.6.2 Hindlimbs step width 
One month KO males have a significant decrease of hindlimbs step width compared with 
WT and HET males. 3 month HET males also have a significant decrease when compared 
with 3 month WT males. There was also a significant difference between WT males and 
females. At 6 months there are no differences between genotypes (table 18). With the 
exception of HET males, the variation in hindlimbs step width over time did not change 
(table 18). 
Table 18 - Hindlimbs steps width results for different genotypes at each time point and 
between males and females within the same genotype and age. 
Hindlimbs step width 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 3,08 ± 0,14 2,63 ± 0,12 * 2,98 ± 0,16 3,18 ± 0,45 2,59 ± 0,09 
(b)
 2,56 ± 0,19 
3 months 2,96 ± 0,11 2, 73 ± 0,11 
ns
 2,56 ± 0,11 
(a)(d)
 2,71 ± 0,18 
ns
 2,49 ± 0,18 2, 74 ±0,12 
ns
 
6 months 2,76 ± 0,14 
ns
 2,78 ± 0,12 
ns
 2,91 ± 0,15
 (f)
 2,76 ± 0,1
 ns
 2,73 ± 0,11 
ns
 2,68 ± 0,14 
ns
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in cm.  * P< 0,05 refers to differences 
between males and females. 
(a)
 P< 0,05 refers to differences between WT and HET. 
(b)
 P< 0,05 refers to differences between 
WT and KO. 
(d)
 P< 0,05 refers to differences between 1month and 3 months. 
(f)
 P< 0,05 refers to differences between 3 
months and 6 months. 1 month WT males n=10; 1 month WT females n=10; 1 month HET males n=10; 1 month HET 
females n=10; 1 month KO males n=7; 1 month KO females n=5; 3 months WT males n=10; 3 months HET males n=10; 3 
months KO males n=7; 6 months HET males n=10. 
 
 
3.2.6.3 Forelimbs step width 
In relation to forelimb step width, the one of WT females at 6 months of age is larger 
compared to KO and HET females. At 1 and 3 months there were no significant 
differences (table 19). KO females had a forelimb step width significant decrease from the 
3rd to the 6th month. WT and HET mice did not show significant differences over time (table 
19). 
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Table 19 - Forelimbs step width results for different genotypes at each time point and 
between males and females. 
Forelimbs step width 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 1,87 ± 0,19 
ns
 1,72 ± 0,12 
ns
 1,69 ± 0,15 
ns
 1,59 ± 0,14 
ns
 1,79 ± 0,23 
ns
 1,44 ± 0,18 
ns
 
3 months 1,77 ± 0,15 
ns
 1,56 ± 0,15 
ns
 1,52 ± 0,07 
ns
 1,62 ± 0,15 
ns
 1,54 ± 0,1 
ns
 1,77 ± 1,11 
ns
 
6 months 1,54 ± 0,15 
ns
 1,8 ± 0,09 1,82 ± 0,14 
ns
 1,55 ± 0,07 
(a)
 1,66 ± 0,12 
ns
 1,46 ± 0,04 
(b)(f)
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in cm.
 (a)
 P< 0,05 refers to differences 
between WT and HET. 
(b)
 P< 0,05 refers to differences between WT and KO. 
(f)
 P< 0,05 refers to differences between 3 
months and 6 months. 3 months KO females n=7; 6 months WT females n=10; 6 months HET females n=10; 6 months KO 
females n=5. 
 
3.2.6.4 Three fingers 
Six month old KO males had larger 3 fingers distance compared with HET and WT males. 
At 1 and 3 month of age there were no significant differences between genotypes. While 
there was a pronounced increase over time in the 3 fingers distance in both KO males and 
females, in WT the increase was only observed between 1 and 3 months of age. No 
variation was observed in HET mice of both sexes. (table 20). 
Table 20 - 3 fingers distance results for different genotypes at each time point and 
between males and females. 
3 fingers 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 0,44 ± 0,02 
ns
 0,36 ± 0,02 
ns
 0,48 ± 0,03 
ns
 0,43 ± 0,03 
ns
 0,4 ± 0,03 
ns
 0,4 ± 0,03 
ns
 
3 months 0,52 ± 0,02 
(d)
 0,52 ± 0,04 
(dd)
 0,49 ± 0,18 
ns
 0,47 ± 0,02 
ns
 0,46 ± 0,04 
ns
 0,49 ± 0,04 
(f)
 
6 months 0,5 ± 0,03 0,52 ± 0,03 
(ee)
 0,49 ± 0,03 0,47 ± 0,02 
ns
 0,59 ± 0,02 
(b)(c)(ee)(f)
 0,50 ± 0,0
 (e)
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in cm.
 (b)
 P< 0,05 refers to differences 
between WT and KO. 
(c)
 P< 0,05 refers to differences between HET and KO. 
(d)
 P< 0,05, 
(dd)
 P< 0,01 refers to differences 
between 1month and 3 months. 
(e)
 P< 0,05,  
(ee)
 P< 0,01 refers to differences between 1 month and 6 months.
 (f)
 P< 0,05 
refers to differences between 3 months and 6 months. 1 month WT males n=10; 1 month WT females n=10; 1 month KO 
males n=7; 1 month KO females n=5; 3 months WT males n=10; 3 months WT females n=9; 3 months KO males n=7; 3 
months KO females n=7; 6 months WT males n=10;  6 months WT females n=10; 6 months HET males n=10; 6 months HET 
females n=10;6 months KO males n=8; 6 months KO females n=5. 
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3.2.6.5 Five fingers 
One month KO females had a 5 fingers distance larger than HET females. One month 
males and 3 and 6 months mice do not have significant differences. KO males had a 
significant increase of 5 fingers distance between the 1st to the 6th month. HET males had 
an increase of 5 fingers distance over time. The 5 fingers distance increased in both HET 
and WT females between the 1st and the 3rd month of age. WT males and KO females did 
not show significant differences (table 21). 
Table 21 - 5 fingers distances results for different genotypes at each time point and 
between males and females. 
5 fingers 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 0,78 ± 0,02 
ns
 0,85 ±  0,01 0,82 ± 0,02 
ns
 0,77 ± 0,04 0,72 ± 0,02 
ns
 0,9 ± 0,03 
(c)
 
3 months 0,91 ± 0,02 
ns
 
0,93 ± 0,02 
(d)
 
0,89 ± 0,01 
(d)
 0,86 ± 0,03 
(d)
 0,84 ± 0,03 
ns
 0,91 ± 0,03 
ns
 
6 months 0,91 ± 0,03 
ns
 0,9 ± 0,04 
(e)
 0,93 ± 0,03 
(e)
 0,87 ± 0,02 
ns
 0,9 ± 0,02 
(e)
 0,82 ± 0,04 
ns
 
Each value is expressed as mean ± SD. ns, not significant. The values are expressed in cm.
 (c)
 P< 0,05 refers to differences 
between HET and KO. 
(d)
 P<0,05 refers to differences between 1month and 3 months. 
(e)
 P< 0,05 refers to differences 
between 1 month and 6 months. 1 month WT females n=10; 1 month HET males n=10; 1 month HET females n=10; 1 
month KO males n=7; 1 month KO females n=5; 3 months WT females n=9; 3 months HET males n=10; 3 months HET 
females n=9; 3 months KO males n=7; 6 months WT females n=10; 6 months HET males n=10; 6 months HET females 
n=10; 6 months KO males n=8. 
 
3.2.6.6 Overlap 
1 month HET females had a significant larger overlap measure when compared to WT. 
One month males and 3 and 6 months mice did not show significant differences. The paws 
overlap measure changed in HET females between the 1st and the 3rd month. There were 
no significant differences between WT, KO mice and HET males over time (table 22). 
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Table 22 - Overlap distances results for different genotypes at each time point and 
between males and females. 
Overlap 
 
WT HET KO 
 
Males Females Males Females Males Females 
1 month 0,45 ± 0,06 
ns
 0,42 ± 0,05 0,45 ± 0,05 
ns
 0,63 ± 0,06 
(aa)
 0,46 ± 0,05 
ns
 0,46 ±0,1 
3 months 0,52 ± 0,04 
ns
 0,6 ± 0,15 
ns
 0,48 ± 0,07 
ns
 0,39 ± 0,06 
(d)
 0,46 ± 0,06 
ns
 
0,45 ± 
0,06 
ns
 
6 months 0,5 ± 0,07 
ns
 
0,53 ± 0,07 
ns
 
0,51 ± 0,04 
ns
 0,48 ± 0,05 
ns
 0,49 ± 0,08 
ns
 
0,4 ± 0,09 
ns
 
Each value is expressed as mean ± SD. ns not significant. The values are expressed in cm.
 (aa)
 P< 0,01 refers to differences 
between WT and HET. 
(d)
 P< 0,05 refers to differences between 1month and 3 months. 1 month WT males n=10; 1 month 
WT females n=10; 1 month HET males n=10; 1 month HET females n=10; 1 month KO males n=7; 1 month KO females 
n=5; 3 months HET females n=9; 6 months HET females n=10. 
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4. Discussion 
Previous work from our and other labs showed Rho GTPase signaling to be essential for 
proper PNS and CNS myelination. However, this work has mainly focused on the functions 
of typical Rho GTPases, and the roles played by the less known atypical Rho GTPases, 
such as the RhoBTB3, in myelination have not yet been investigated. 
Therefore, and in collaboration with the lab of Francisco Rivero (University of Hull, UK), we 
have started analyzing potential myelin defects in RhoBTB3 null mice. Our preliminary 
results show profound hypomyelination of the optic nerve, but not of other central nervous 
system (CNS) regions (figure 6). The reasons of this regional specificity are not clear and 
are currently being investigated in our lab (Filipa Domingues, unpublished data). 
To screen for other potential nervous system phenotypes, we chose to use a standardized 
set of experimental procedures, known as SHIRPA. Although using relatively simple and 
inexpensive equipment, SHIRPA has successfully been used to detect neurological 
defects in genetic modified laboratory mice.  It requires equal house and cage conditions 
for all mice being tested and, more importantly, access to a large number of mice to 
reduce result variability (Brown RE, Stanford L 2000). 
In this project, the availability of RhoBTB3 KO mice has been a problem, as they are born 
at a sub-Mendelian frequency. Such lower frequency of born mutants, most likely due to  
increased intrauterine death, warrants further investigation. RhoBTB3 KO post-natal 
mortality is also slightly increased in our colony at the IBMC (data not shown), and viable 
mutant male and female mice are also significantly lighter and noticeably smaller (figure 
13) than controls. This is in line with the phenotyping data provided by the Sanger Institute 
(Cambridge, UK) concerning RhoBTB3 mutant mice 
(http://www.sanger.ac.uk/mouseportal/search?query=rhobtb3). RhoBTB3 co-localizes with 
vesicular structures within the cell suggesting a role on endocytosis. Similarly to what we 
have described for cdc42 mutant mice, compromised endocytosis can affect pathways 
essential for cell proliferation and growth (Bumann, unpublished results). 
For convenience and to shorten the discussion, I opted to focus on the tests in which 
significant statistical differences were detected. There were some statistical significant 
differences between KOs, heterozygous (HET) and control mice in the SHIRPA tests 
performed in the arena. In the Touch escape test, KOs showed a decreased ability to react 
to the touch having slower escape responses compared to WT mice. In the transfer 
arousal, locomotors activity and tail elevation tests, only HET mice showed differences 
over time. As in these tests KO mice were not affected, it is difficult to draw any valid 
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conclusion on the putative effects of the lack of RhoBTB3 in motor ability. Therefore, more 
specific tests should be carry out to test for motor ability, such as rotarod and open fields 
tests. 
The Visual placing test is used for checking the visual acuity. Given the myelin defects 
present in the mutant optic nerve, it was particularly important to check if there was a 
difference between control and mutant mice. This was indeed the case. Although at one 
month of age the result variability was too high to reach any conclusion, at 6 months the 
visual accuracy of KO mice was less than that of WT mice. HET mice also presented a 
significant decrease in visual acuity compared to WT, although not as severe as in KO 
mice. These data suggest that the lack of RhoBTB3 reduces visual acuity. To confirm such 
a phenotype more accurate tests should be carried out, including those that do not depend 
on the behavior of the conscious animal such as the electroretinogram and the visual 
evoked potentials of the cortex (Pinto & Enroth-Cugell 2000). Both these tests assess the 
structure and function of the visual system reliably and complement the ongoing 
histological analysis of both the retina and optic nerve being carried out in our lab.   
There was a significant reduction in grip strength between KOs and controls at 3 months 
(12 weeks). The Grip strength was reported by the Sanger Institute to be decreased in 9 
week RhoBTB3 KO females and accordingly, our data show a reduction in Grip Strength in 
RhoBTB3 KO mice (both genders) compared to controls. Such reduction can be related to 
a decrease of neuromuscular function. As RHOBTB3 is highly expressed in nervous and 
muscular tissue, this warrants further investigation at both histological and behavioral 
levels. Although the toe pinch reflex (pedal withdraw reflex) tests did not show significant 
differences between mutant and controls, suggesting that the lack of RhoBTB3 does not 
affect the capacity of processing noxious stimuli, other behavioral models of nociception 
such as for example the hot plate test, could be used to strengthen this conclusion. 
Somehow surprisingly, KO and HET mice performed better than WT mice in the Wire 
Maneuver test and the differences became significant at 6 months of age. These results 
can be related with the possibility of KO mice have difficulty in see the arena floor, and 
then have afraid of falling. In order to provide relevant information the Wire Maneuver test 
should in the future be performed with the increase of the wire height. 
KO mice have significant higher heart rate compared with HET and WT mice. RhoBTB3 is 
strongly expressed in the heart suggesting a putative role in cardiac function for this 
protein. This issue warrants further investigation both at functional and histological level. 
There were no significant differences in the number of urination occurrences (micturation) 
between WT and KO mice. 
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The footprint test was used to compare the gait between genotypes. Different 
measurements between footfalls provide a description of the gait of the mouse, and 
parameters such as frontbase and hindbase width, overlap, 3 and 5 fingers distance were 
considered. Significant alterations in forelimb step width between WT, HET and KO 
females and in 3 fingers and 5 fingers distance were observed between KO and WTs. 
Some of these differences could suggest defects in motor coordination. However, as 
mutant mice were significantly smaller than HET and WT, the differences observed 
between genotypes can, at least in part, be explained by differences in body size. 
Therefore, other tests evaluating balance and motor coordination such as for example the 
rotarod test should be performed. 
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5. Conclusions and Future Perspectives 
In this study, I used SHIRPA to detect neurological and physiological abnormalities, and 
the general health status of mutant RhoBTB3 mutant mice.  
Absence of RhoBTB3 led to significant changes in weight and heart rate and in some of 
the behaviour tests carried out, such as for example the touch escape test and the grip 
strength test. Some of these tests suggest that RhoBTB3 mutants have decreased visual 
acuity, which is consistent with the dysmyelination phenotype observed in the optic nerve, 
and some less evident impairments in neuromuscular function. 
I will increase the number of mice being tested and will perform more specific behavioral 
tests like rotarod, hot plate and open-field. To further characterize visual acuity in 
RhoBTB3 mutant mice, we will carry out maze-based tests, elevated plus maze, visual 
cliff, optomotor responses, visually evoked potentials, electroretinography and fundus 
examination (Pinto & Enroth-Cugell 2000; Prusky et al. 2004). Histopathologic analysis will 
also be carried out when necessary to confirm potential phenotypes suggested by the 
SHIRPA protocol. 
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